| Name | Title | Contact Details |
|---|
This website is for sale! fitnessconnectionusa.com is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, fitnessconnectionusa.com has it all. We hope you find wha...
At Fractyl, we are focused on improving the health of people with Type 2 diabetes. We`ve created an innovative clinical procedure based on new insights into the root cause of the disease. We are currently engaged in clinical trials designed to prove that our innovative procedure can dramatically improve glucose control and reduce the need for additional medications. Our mission is to set people free from the daily burdens of Type 2 diabetes management, empower physicians with a safe and reliable therapeutic treatment, and lower the tremendous human and financial costs of diabetic complications for patients, hospitals, and payers.
Mason Wright Retirement Cmnty is a Springfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
Andwin Scientific specializes in product distribution both as a distributor to direct end using companies, and as a supplier/vendor to national and international supply houses. This effort is supported by offices in North Carolina and Illinois